Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ethan Casey

Physician Assistant, Medical Spartanburg, SC Physician Assistant

NPI 1750045423 CMS profile 11290990

1650 Skylyn Dr, Spartanburg, SC 29307

Open in the dashboard

General payments

$24,311

1,019 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ethan Casey of Spartanburg, SC is reported in the CMS Open Payments database as having received $24,311 across 1,019 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,104 248
2024 General $8,602 291
2023 General $5,850 264
2022 General $4,253 206
2021 General $501 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ethan Casey
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Ethan Casey were reported at $5,104. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Ethan Casey Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $501 $156 $41–$563 $132
2022 $4,253 $185 $55–$649 $149
2023 $5,850 $199 $58–$717 $160
2024 $8,602 $206 $62–$740 $164
2025 $5,104 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,372 195 payments
  2. UCB, Inc. $3,005 36 payments
  3. E.R. Squibb & Sons, L.L.C. $2,340 68 payments
  4. Sun Pharmaceutical Industries Inc. $1,980 67 payments
  5. LEO Pharma Inc. $1,895 58 payments
  6. Janssen Biotech, Inc. $1,601 73 payments
  7. Pfizer Inc. $1,280 63 payments
  8. Novartis Pharmaceuticals Corporation $1,266 77 payments
  9. Lilly USA, LLC $1,257 65 payments
  10. Incyte Corporation $1,252 59 payments
  11. Other $5,063 258 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $20,050 1,001 payments
  2. Consulting Fee $3,276 4 payments
  3. Education $892 11 payments
  4. Travel and Lodging $93 3 payments
Products named General payments · program years 2021–2025
  1. Bimzelx $2,922 32 payments
  2. TREMFYA $1,865 76 payments
  3. ADBRY $1,617 47 payments
  4. RINVOQ $1,435 76 payments
  5. SKYRIZI $1,357 96 payments
  6. CIBINQO $1,236 61 payments
  7. ILUMYA $1,208 48 payments
  8. OPZELURA $1,180 58 payments
  9. Otezla $1,159 56 payments
  10. SOTYKTU $1,155 59 payments
  11. Other $10,245 530 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

2,264

Median for Physician Assistant: 241

Drug cost

$1,566,499

Median for Physician Assistant: $4,110

Branded share of claims

10.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 129 $537,194
Skyrizi Pen Risankizumab-Rzaa Brand 24 $503,340
Tremfya Guselkumab Brand 12 $167,254
Cosentyx Unoready Pen Secukinumab Brand 16 $160,544
Humira(Cf) Pen Adalimumab Brand 13 $142,305
Tacrolimus Generic 111 $16,735
Clobetasol Propionate Generic 262 $8,854
Ketoconazole Generic 330 $4,936
Triamcinolone Acetonide Generic 261 $4,402
Fluocinolone Acetonide Generic 101 $3,553

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$255,075

Of which drugs: $125,528

Medicare patients

836

Average age 74

Services billed

5,432

396 women, 440 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 46%
Diabetes 30%
Chronic kidney disease 28%
Ischemic heart disease 24%
Depression 19%
Atrial fibrillation 17%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 13 27 $7,786

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Bimzelx
$2,459 — —
ADBRY
$814 — —
TREMFYA
$609 12 —
SKYRIZI
$545 24 —
RINVOQ
$522 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

1,019 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record